BJDX

Bluejay Diagnostics, Inc.

7 filings tracked

healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 7

Insider-led private placement in March 2026 shows management confidence.

capital raise

40%

bearishMay 7

Negative cash flows and significant accumulated deficit raise going concern doubts.

margin compression

70%

bearishMay 7

Massive warrant overhang and history of reverse splits indicate high dilution risk.

dilution risk

90%

bullishMay 7

Insider-led private placement in March 2026 shows management confidence.

capital raise

40%

bearishMay 7

Negative cash flows and significant accumulated deficit raise going concern doubts.

margin compression

70%

bearishMay 7

Massive warrant overhang and history of reverse splits indicate high dilution risk.

dilution risk

90%

bullishMay 7

Insider-led private placement in March 2026 shows management confidence.

capital raise

40%

bearishMay 7

Negative cash flows and significant accumulated deficit raise going concern doubts.

margin compression

70%

bearishMay 7

Massive warrant overhang and history of reverse splits indicate high dilution risk.

dilution risk

90%

bullishMay 7

Insider-led private placement in March 2026 shows management confidence.

capital raise

40%

bearishMay 7

Negative cash flows and significant accumulated deficit raise going concern doubts.

margin compression

70%

bearishMay 7

Massive warrant overhang and history of reverse splits indicate high dilution risk.

dilution risk

90%

bullishMay 7

Insider-led private placement in March 2026 shows management confidence.

capital raise

40%

bearishMay 7

Negative cash flows and significant accumulated deficit raise going concern doubts.

margin compression

70%

bearishMay 7

Massive warrant overhang and history of reverse splits indicate high dilution risk.

dilution risk

90%

bullishMay 7

Insider-led private placement in March 2026 shows management confidence.

capital raise

40%

bearishMay 7

Negative cash flows and significant accumulated deficit raise going concern doubts.

margin compression

70%

bearishMay 7

Massive warrant overhang and history of reverse splits indicate high dilution risk.

dilution risk

90%

bullishMay 7

Insider-led private placement in March 2026 shows management confidence.

capital raise

40%

bearishMay 7

Negative cash flows and significant accumulated deficit raise going concern doubts.

margin compression

70%

bearishMay 7

Massive warrant overhang and history of reverse splits indicate high dilution risk.

dilution risk

90%

Filing History

10-QMay 7, 2026

The 10-Q filing reveals a company locked in a race between clinical success and financial exhaustion. While the progress of the SYMON-II trial is a tangible positive, the 'going concern' warning is the dominant signal. Bluejay has a clear technical roadmap and a high-value target market, but its ability to execute that roadmap is entirely contingent on its ability to raise $20 million in a challenging capital environment. Investors are essentially weighing the probability of a positive clinical readout against the certainty of imminent dilution. The company's survival depends on whether the near-completion of the SYMON-II study can attract enough institutional capital to bridge the gap to a 2027 FDA submission. Until a significant financing event occurs, the stock remains a binary play on clinical validation and liquidity management.